A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BRINCIDOFOVIR (BCV) VERSUS VALGANCICLOVIR (VGCV) FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN CMV-SEROPOSITIVE KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED ANTILYMPHOCYTE INDUCTION THERAPY
- Registry ID
- CMX001-307
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- CHIMERIX INC
- Last update
- 2015-12-17
Conditions
Related clinical trials
- LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS IN PEDIATRIC HEMATOPOIETIC CELL
TRANSPLANTATION
- A PHASE 3, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF MRNA-1647 CYTOMEGALOVIRUS (CMV) VACCINE IN HEALTHY PARTICIPANTS 16 TO 40 YEARS OF AGE
- DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY AND IMMUNOGENICITY OF A 2-DOSE AND A 3-DOSE REGIMEN OF V160 (CYTOMEGALOVIRUS [CMV] VACCINE) IN HEALTHY SERONEGATIVE WOMEN, 16 TO 35 YEARS OF AGE
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL TO EVALUATE THE PROECTIVE EFFICACY AND SAFETY OF A THERAPUTIC VACCINE, ASPO113, IN CYTOMEGALOVIRUS (CMV)- SEROPOSTIVIVE RECIPIENTS UNDERGOING ALLOGENIC, HEMATOPOIETIC CELL TRANSPLANT (HCT).
View on source registry